Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 9.50% | -7.06% | -11.38% | -43.70% | -63.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.50% | -7.06% | -11.38% | -43.70% | -63.67% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 9.50% | -7.06% | -11.38% | -43.70% | -63.67% |
| SG&A Expenses | -22.02% | -23.14% | -20.69% | 18.42% | 99.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.55% | 0.15% | -4.96% | 23.20% | 75.50% |
| Operating Income | -9.55% | -0.43% | 4.64% | -28.78% | -95.54% |
| Income Before Tax | -3.29% | 4.53% | 8.37% | -26.76% | -96.85% |
| Income Tax Expenses | -13.47% | -0.28% | 7.90% | -8.23% | -33.93% |
| Earnings from Continuing Operations | -1.63% | 5.35% | 8.46% | -30.59% | -113.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.63% | 5.35% | 8.46% | -30.59% | -113.14% |
| EBIT | -9.55% | -0.43% | 4.64% | -28.78% | -95.54% |
| EBITDA | -8.98% | 1.06% | 7.15% | -26.08% | -93.64% |
| EPS Basic | 14.40% | 18.52% | 18.61% | -19.89% | -93.80% |
| Normalized Basic EPS | 12.15% | 16.48% | 17.75% | -16.91% | -77.45% |
| EPS Diluted | 14.40% | 18.52% | 18.61% | -19.89% | -93.80% |
| Normalized Diluted EPS | 12.15% | 16.48% | 17.75% | -16.91% | -77.45% |
| Average Basic Shares Outstanding | 16.48% | 13.25% | 10.03% | 12.66% | 15.71% |
| Average Diluted Shares Outstanding | 16.48% | 13.25% | 10.03% | 12.66% | 15.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |